The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% (5mg), 21.4% (10mg), and 22.5% (15mg) over 72 weeks
Clinical trials show both drugs cause gastrointestinal symptoms, but tirzepatide's action on two hormone receptorsGLP-1 and GIPcreates a unique tolerability signature that differs from semaglutide's single-pathway approach
Morgan analyst Chris Schott wrote in an investor note
Scientific References Benoist, C
Save Face investigates vitamin B12 booster injections, finding out why we need B12, vitamin deficiency, and the different types of B12 options available Whether its intravenous (IV) vitamin drips, IV nutritional infusion cocktails, or vitamin shots, it seems that the trend for booster injections is a growth market in the UK, especially vitamin B12
Supporting information Acknowledgement Open access publishing facilitated by Monash University, as part of the Wiley Monash University agreement via the Council of Australian University Librarians
